KR20230048358A - 질환 및 장애를 치료하기 위한 조성물 및 방법 - Google Patents

질환 및 장애를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20230048358A
KR20230048358A KR1020237007466A KR20237007466A KR20230048358A KR 20230048358 A KR20230048358 A KR 20230048358A KR 1020237007466 A KR1020237007466 A KR 1020237007466A KR 20237007466 A KR20237007466 A KR 20237007466A KR 20230048358 A KR20230048358 A KR 20230048358A
Authority
KR
South Korea
Prior art keywords
compound
subject
pharmaceutical composition
disease
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237007466A
Other languages
English (en)
Korean (ko)
Inventor
라인하르트 본 로에멜링
엘리자베스 마르티네즈
로버트 마르텔
Original Assignee
쿠리스 인코퍼레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쿠리스 인코퍼레이션 filed Critical 쿠리스 인코퍼레이션
Publication of KR20230048358A publication Critical patent/KR20230048358A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237007466A 2020-08-03 2021-04-30 질환 및 장애를 치료하기 위한 조성물 및 방법 Pending KR20230048358A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063060413P 2020-08-03 2020-08-03
US63/060,413 2020-08-03
US202063115312P 2020-11-18 2020-11-18
US63/115,312 2020-11-18
PCT/US2021/030192 WO2022031330A1 (en) 2020-08-03 2021-04-30 Compositions and methods for treating diseases and disorders

Publications (1)

Publication Number Publication Date
KR20230048358A true KR20230048358A (ko) 2023-04-11

Family

ID=80117618

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237007466A Pending KR20230048358A (ko) 2020-08-03 2021-04-30 질환 및 장애를 치료하기 위한 조성물 및 방법

Country Status (12)

Country Link
US (1) US20230310444A1 (https=)
EP (1) EP4188368A4 (https=)
JP (1) JP2023537477A (https=)
KR (1) KR20230048358A (https=)
CN (1) CN116419752A (https=)
AU (1) AU2021321350A1 (https=)
BR (1) BR112023001861A2 (https=)
CA (1) CA3188171A1 (https=)
CU (1) CU20230009A7 (https=)
IL (1) IL300310A (https=)
MX (1) MX2023001296A (https=)
WO (1) WO2022031330A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3466955T (lt) 2014-01-13 2021-02-25 Aurigene Discovery Technologies Limited Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
EP4319750A4 (en) 2021-04-08 2025-02-26 Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
WO2023172640A1 (en) * 2022-03-08 2023-09-14 X4 Pharmaceuticals, Inc. Treatments for single-mutant waldenström's macroglobulinemia
JP2025516501A (ja) * 2022-05-11 2025-05-30 キュリス，インコーポレイテッド Ｉｒａｋ４修飾化合物による疾患及び障害の治療
WO2024027750A1 (en) * 2022-08-02 2024-02-08 Beigene Switzerland Gmbh Methods of treating pulmonary hypertension using btk inhibitors
WO2025208000A1 (en) * 2024-03-29 2025-10-02 Curis, Inc. Methods of treating cancer in patients with altered protein expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3466955T (lt) * 2014-01-13 2021-02-25 Aurigene Discovery Technologies Limited Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
TW201701879A (zh) * 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
US20170035881A1 (en) * 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
EP3600270B1 (en) * 2017-03-31 2023-06-14 Aurigene Oncology Limited Compounds and compositions for treating hematological disorders
HUE067356T2 (hu) * 2017-10-31 2024-10-28 Curis Inc IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra
EP3800188A1 (en) * 2019-10-02 2021-04-07 Bayer AG Substituted pyrazolopyrimidines as irak4 inhibitors
MX2023005591A (es) * 2020-11-18 2023-05-29 Curis Inc Metodos de tratamiento de enfermedades y trastornos.
EP4319750A4 (en) * 2021-04-08 2025-02-26 Curis, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
US20230310444A1 (en) 2023-10-05
BR112023001861A2 (pt) 2023-03-07
CA3188171A1 (en) 2022-02-10
CN116419752A (zh) 2023-07-11
CU20230009A7 (es) 2023-09-07
WO2022031330A1 (en) 2022-02-10
EP4188368A4 (en) 2024-09-04
JP2023537477A (ja) 2023-09-01
AU2021321350A1 (en) 2023-03-16
MX2023001296A (es) 2023-02-22
EP4188368A1 (en) 2023-06-07
IL300310A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
KR20230048358A (ko) 질환 및 장애를 치료하기 위한 조성물 및 방법
TWI651311B (zh) 用於合成吲哚胺２，３－雙加氧酶抑制劑之方法
US20230414582A1 (en) Methods of treating diseases and disorders
CN113038945A (zh) 细胞因子释放综合征的治疗方法
EP4041239B1 (en) A pyrrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases
BR112021008781A2 (pt) combinação de inibidores de cd-47 de pequena molécula com outros agentes anticâncer
US12178821B2 (en) Combination therapies for the treatment of cancer
JP2022546806A (ja) 癌免疫療法
JP2025516501A (ja) Ｉｒａｋ４修飾化合物による疾患及び障害の治療
EP4719407A1 (en) Methods of treating cancer in subjects with prior immune checkpoint inhibitor exposure
KR20260018053A (ko) Bcl2 억제제에 노출 이력이 없는 대상체의 암 치료 방법
HK40092945A (zh) 用於治疗疾病和病症的组合物和方法
WO2020242910A1 (en) Compositions and methods for treating cancer
HK40096682A (zh) 治疗疾病和病症的方法
EA052069B1 (ru) Способы лечения заболеваний и расстройств
CN121969366A (zh) 治疗与白介素1β表达降低相关的癌症的方法
HK40120966A (zh) 用irak4修饰化合物治疗疾病和病症
KR20250044649A (ko) X-ald 치료를 위한 갑상선 베타-작용제 투여 요법
EA047718B1 (ru) Способ модуляции сигнальных путей tigit и pd-1 с применением 1,2,4-оксадиазольных соединений

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230302

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240429

Comment text: Request for Examination of Application